Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with mild to severe Alzheimer's disease (probable or possible), with measurable signs of memory or thinking problems confirmed at a screening visit
• People who score 0.5 or higher on a standard dementia rating scale called the CDR (Clinical Dementia Rating Scale)
• People who are taking medication for Alzheimer's symptoms, provided the dose has remained the same for at least 8 weeks before the screening visit
• People whose blood counts, liver function, and kidney function all fall within acceptable ranges as determined by blood tests at the screening visit (confirm specific values with trial site)
• Women who could become pregnant must have a negative pregnancy blood test at screening, and must either have had a surgical procedure that prevents pregnancy, have been through menopause for at least one year, or agree to use two forms of contraception throughout the study
• Women who could become pregnant must agree to use highly effective contraception during the study, such as an intrauterine device plus a barrier method, hormonal contraception plus a barrier method, or two barrier methods used together
• Men must agree to use an adequate form of contraception, such as a condom, during the study
• The person joining, or their legal representative or guardian, must be willing to sign a consent form and follow all study requirements

Who may not be able to join:

• People who weigh 150 kg or more, or whose body mass index (BMI) is 35 or higher at the screening visit
• People who have used a specific type of drug targeting a protein called CSF-1 or its receptor (including pexidartinib/Turalio) within 3 months before the first study dose
• People whose genetic makeup means a particular brain-imaging tracer used in the study does not bind well in the brain (a specific genetic variation called TSPO rs6971 SNP low-binding polymorphism — confirm with trial site)
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study
• People with active tuberculosis, active or chronic hepatitis B, hepatitis C, or HIV infection
• People with another medical or brain-related condition — other than Alzheimer's disease — that the study doctor believes could be causing or contributing to their memory and thinking problems, or that could interfere with study participation
• People with significant unstable mental health conditions, or those who are unable to safely undergo brain MRI or PET scans
• People who have had a stroke, a mini-stroke (TIA), unexplained loss of consciousness, or significant bleeding in the brain within the past year
• People with significant ongoing conditions affecting the stomach, heart, liver, kidneys, blood, hormones, lungs, immune system, or other major body systems, as judged by the study doctor — including poorly controlled type 2 diabetes, or cognitive decline linked to causes such as vitamin B12 deficiency, thyroid problems, or substance use; people who require tube feeding are also excluded
• People with a current or recent history of cancer requiring treatment, except for certain minor skin cancers or very early-stage cancers that have been adequately treated
• People currently in another clinical trial, or who have participated in a clinical trial within the last 60 days before screening; people who have donated 250 mL or more of blood within 30 days before screening
• People with a known allergy or sensitivity to the study drug (EI-1071) or any of its ingredients, or to the imaging tracers used in the study
• People who need to take certain medications that strongly affect how the body processes the study drug (strong CYP3A4 inhibitors or inducers — confirm specific medications with trial site)

Important: Always verify eligibility with the trial site directly before applying.